Clinical outcome of febrile neutropenia in children with cancer using ceftazidime and aminoglycosides.
To determine treatment outcome using ceftazidime-aminoglycosides in febrile neutropenic children with cancer, the authors conducted a prospective cohort study in 216 episodes. Early and complete responses to antibiotics were 108/216 (50.0%) and 133/216 (61.6%) episodes, respectively. Death, a modification of antibiotic(s), and resistance to ceftazidime were 2/118 (1.7%), 73/216 (33.8%), and 4/216 (1.9%) episodes, respectively. Primary bacteremia and emerging bacteremia during treatment were 20/216 (9.3%) and 5/216 (2.3%) episodes. Ceftazidime-aminoglycosides was found to be a reasonable initial treatment of febrile neutropenia in the authors' institution. Imipenem is considered in patients who have clinical sepsis and who fail to respond to initial treatment.
Laoprasopwattana
Kamolwish
K
Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand. kamolwish@yahoo.com
Pruekprasert
Pornpimol
P
Laosombat
Vichai
V
Wongchanchailert
Malai
M
D000293:Adolescent; D000583:Amikacin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D016470:Bacteremia / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D002442:Ceftazidime / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage; D017408:Guidelines as Topic; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage; D007223:Infant; D008297:Male; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy / Q000401:mortality; D009503:Neutropenia / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D011446:Prospective Studies; D015996:Survival Rate
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D015378:Imipenem; D000583:Amikacin; D002442:Ceftazidime